Vyriad Announces Strategic Collaboration With Novartis to Develop in Vivo CAR-T Cell Therapies
Vyriad Announces Strategic Collaboration With Novartis to Develop in Vivo CAR-T Cell Therapies
"Taking an Collaboration will combine Vyriad's lentiviral vector platform and Novartis expertise and leadership in cell therapy innovation
此次合作将结合Vyriad的慢病毒载体平台和诺华在细胞治疗创新方面的专业知识和领导能力
ROCHESTER, Minn., Nov. 20, 2024 /PRNewswire/ -- Vyriad, Inc., a clinical-stage biotechnology company developing the next generation of targeted genetic therapies, today announced a strategic collaboration with Novartis to discover and develop in vivo chimeric antigen receptor (CAR) T-cell therapies.
罗切斯特，明尼苏达州，2024年11月20日 /PRNewswire/ -- Vyriad, Inc.是一家临床阶段的生物技术公司，正在开发下一代靶向基因治疗，今天宣布与诺华达成战略合作，发现并开发体内嵌合抗原受体（CAR）T细胞疗法。
The collaboration will leverage Vyriad's active targeting lentiviral vector platform and Novartis expertise and leadership in cell therapy innovation. Novartis and Vyriad will focus on the identification and development of in vivo CAR-T cell therapy candidates to be clinically advanced by Novartis. Vyriad will receive an upfront payment, milestone payments, and tiered royalties on each program.
此次合作将利用Vyriad的主动靶向慢病毒载体平台和诺华在细胞治疗创新方面的专业知识和领导能力。诺华和Vyriad将专注于体内CAR-T细胞治疗候选药物的识别和开发，以便诺华在临床上推进。Vyriad将获得前期付款、里程碑付款和每个项目的分级版税。
"Taking an in vivo approach to CAR-T cell therapies has the potential to transform the field," said Vyriad CEO Stephen J. Russell, M.D. Ph.D. "We believe our targeted delivery platform is poised to enable this vision for the industry and our collaboration with Novartis represents an exciting step forward in advancing the next generation of CAR-T cell treatments."
“采用体内方法进行CAR-T细胞疗法有潜力改变这一领域，”Vyriad首席执行官Stephen J. Russell万.D.博士说。“我们相信我们的靶向递送平台有望实现这一行业愿景，而我们与诺华的合作代表着推进下一代CAR-T细胞治疗的重要一步。”
"As an industry pioneer in the field, we are committed to addressing unmet medical needs and making the transformative potential of CAR-T cell therapies available to more patients," said Jennifer Brogdon, Head of Cell & Gene Therapies at Novartis Biomedical Research. "We are excited to collaborate with Vyriad and combine their technology platform with Novartis expertise and capabilities to innovate and advance next-generation CAR-T cell therapies."
“作为该领域的行业先锋，我们致力于满足未被满足的医疗需求，并使CAR-T细胞疗法的变革潜力能够惠及更多患者，”诺华生物医学研究的细胞和基因治疗负责人Jennifer Brogdon表示。“我们很高兴能与Vyriad合作，将他们的技术平台与诺华的专业知识和能力相结合，以创新和推进下一代CAR-T细胞疗法。”
Vyriad's targeted lentiviral vector platform provides T-cell specificity and activation in vivo, enabling delivery of CAR payloads to T cells in their natural environment. Through its viral vector engineering acumen, Vyriad developed a lentiviral delivery system with the potential to target and transduce resting T cells and reprogram them while still inside the body to become potential treatments for patients.
Vyriad的靶向慢病毒载体平台在体内提供T细胞特异性和激活，能够将CAR载荷递送到其自然环境中的T细胞。通过其病毒载体工程的专业知识，Vyriad开发了一种慢病毒递送系统，具有靶向和转导静止T细胞并在体内重新编程的潜力，从而成为患者的潜在治疗方案。
About Vyriad, Inc.
Vyriad is a clinical-stage biotechnology company developing the next generation of targeted genetic therapies using engineered viruses, viral vectors and viral envelope glycoproteins to deliver genes directly to targeted cells. This targeting technology facilitates oncolytic virotherapy, in vivo gene therapies and gene editing applications. Phase 1-2 trials with our oncolytic viruses, both as monotherapies and in combination with immune-oncology drugs, are underway in multiple cancer indications in collaboration with Regeneron, Mayo Clinic and other research and medical institutions. Vyriad is a privately held company based in Rochester, Minnesota. For more information, visit .
关于Vyriad公司。
Vyriad是一家临床阶段的生物技术公司，正在开发下一代靶向基因疗法，使用工程化病毒、病毒载体和病毒包膜糖蛋白直接将基因递送到靶细胞。这项靶向技术促进了溶瘤病毒疗法、体内基因疗法和基因编辑应用。目前，与Regeneron、梅奥诊所和其他研究及医疗机构合作，正在进行我们溶瘤病毒的第一和第二期试验，作为单一疗法和与免疫肿瘤药物联合使用，针对多种癌症适应症。Vyriad是一家总部位于明尼苏达州罗切斯特的私人公司。如需更多信息，请访问 .
Vyriad Media Inquiries
For inquiries, please contact [email protected]
Vyriad媒体咨询
如有咨询，请联系 [email protected]
SOURCE Vyriad, Inc.
来源：Vyriad公司。